Fatty-Acid Binding Protein 4 (FABP4) as a Potential Preclinical Biomarker of Drug-Induced Kidney Injury

Toxicological Sciences : an Official Journal of the Society of Toxicology
Jana ObajdinVitalina Gryshkova

Abstract

Identification of improved translatable biomarkers of nephrotoxicity is an unmet safety biomarker need. Fatty-acid-binding protein 4 (FABP4) was previously found to be associated with clinical renal dysfunction and was proposed as a biomarker of glomerular damage. The aim of this study was to evaluate FABP4 as a potential preclinical biomarker of drug-induced kidney injury (DIKI). Han-Wistar rats were dosed with cisplatin [2.5 mg/kg, single, intraperitoneally (i.p.)], puromycin (10 mg/kg, daily, i.p.) or N-phenylanthranylic acid [NPAA, 500 mg/kg, daily, per os (p.o.)] over a 28-day period to induce proximal tubule, glomerular or collecting duct injury, respectively. An increase in urinary FABP4 levels was observed on days 1 and 3 after NPAA treatment and on days 14, 21, and 28 after puromycin treatment, whereas cisplatin treatment had no effect. No significant changes were reported for plasma levels of FABP4 after any treatment. Interestingly, immunohistochemical analysis showed a marked decrease in FABP4 expression in the loop of Henle on day 7 after NPAA treatment and a complete loss of FABP4 expression on day 14 after puromycin treatment. The magnitude of increase in FABP4 urinary levels in response to NPAA and puromycin was...Continue Reading

References

Jun 16, 2004·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Rebecca E WilliamsEdward A Lock
Aug 3, 2004·Nature Reviews. Drug Discovery·Ismail Kola, John Landis
Feb 24, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Tsukasa NakamuraHikaru Koide
Oct 19, 2007·Journal of the American Society of Nephrology : JASN·Tokunori YamamotoTakeshi Sugaya
Sep 20, 2008·Nephron. Clinical Practice·Sushrut S Waikar, Joseph V Bonventre
Nov 21, 2008·American Journal of Physiology. Renal Physiology·Eisei NoiriTakeshi Sugaya
Dec 19, 2009·Handbook of Experimental Pharmacology·Thomas D Nolin, Jonathan Himmelfarb
May 12, 2010·Nature Biotechnology·Joseph V BonventreFrank Dieterle
May 10, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Maryam NejatZoltán H Endre
Nov 10, 2011·Toxins·Ronald P MillerWilliam Brian Reeves
Sep 28, 2012·Critical Care : the Official Journal of the Critical Care Forum·Marlies OstermannLui G Forni
Mar 12, 2013·Critical Care Research and Practice·Evdoxia TsigouGeorge Baltopoulos
Jun 28, 2013·British Journal of Clinical Pharmacology·Euan A SandilandsDavid J Webb
Nov 14, 2013·British Journal of Clinical Pharmacology·Leonie van MeerJacobus Burggraaf
Apr 16, 2014·BioMed Research International·Alexandre Braga LibórioCandice Torres de Melo Bezerra
May 13, 2014·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·T EbertM Fasshauer
May 17, 2014·Nature Reviews. Drug Discovery·David CookMenelas N Pangalos
Dec 3, 2014·Biochemical and Biophysical Research Communications·Shota OzawaTakahiko Nakagawa
Aug 9, 2015·Toxicological Sciences : an Official Journal of the Society of Toxicology·Rounak NassirpourLaurence O Whiteley
Jul 5, 2016·Critical Care : the Official Journal of the Critical Care Forum·James F Doyle, Lui G Forni
Jul 27, 2017·Scandinavian Journal of Clinical and Laboratory Investigation·Dinah S KhatirNiels H Buus

❮ Previous
Next ❯

Related Concepts

Related Feeds

Related Papers

Toxicological Sciences : an Official Journal of the Society of Toxicology
Stéphanie F GlineurAndré Nogueira da Costa
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
Jay L KoynerTranslational Research Investigating Biomarker Endpoints in AKI (TRIBE AKI) Consortium
© 2022 Meta ULC. All rights reserved